Nucleoside-Analogue Reverse-Transcriptase Inhibitors Plus Nevirapine, Nelfinavir, or Ritonavir for Pretreated Children Infected with Human Immunodeficiency Virus Type 1

• Published in: Clinical infectious diseases Vol. 34; no. 7; pp. 991 - 1001
• Main Authors: Krogstad, Paul, Lee, Sophia, Johnson, George, Stanley, Kenneth, McNamara, James, Moye, John, Jackson, J. Brooks, Aguayo, Rosaura, Dieudonne, Arry, Khoury, Margaret, Mendez, Hermann, Nachman, Sharon, Wiznia, Andrew
• Format: Journal Article
• Language: English
• Published: Chicago, IL The University of Chicago Press 01.04.2002; University of Chicago Press
• Subjects: AIDS; Anti-HIV Agents - adverse effects; Anti-HIV Agents - therapeutic use; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiretrovirals; Antiviral agents; Biological and medical sciences; CD4-Positive T-Lymphocytes - drug effects; Child; Child health services; Child, Preschool; Children; Clinical trials; Drug Therapy, Combination; Female; HIV; HIV 1; HIV Infections - drug therapy; HIV/AIDS; Human viral diseases; Humans; Infectious diseases; Lamivudine - therapeutic use; Male; Medical sciences; Nelfinavir - adverse effects; Nelfinavir - therapeutic use; Nevirapine - adverse effects; Nevirapine - therapeutic use; Pediatrics; Pharmacology. Drug treatments; Reverse Transcriptase Inhibitors - adverse effects; Reverse Transcriptase Inhibitors - therapeutic use; Ritonavir - adverse effects; Ritonavir - therapeutic use; RNA; RNA, Viral - drug effects; RNA, Viral - metabolism; Stavudine - therapeutic use; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Virology; RNA-directed DNA polymerase; Nevirapine; HIV-1 virus; Ritonavir; Non nucleoside compound; Reverse transcriptase inhibitor; Nelfinavir; Antiviral; Child; Human; Immunopathology; Drug combination; Enzyme; Transferases; Retroviridae; Enzyme inhibitor; AIDS; Immune deficiency; Lentivirus; Infection; Virus; Peptidases; Nucleotidyltransferases; Chemotherapy; Treatment; Viral disease; Hydrolases; Human immunodeficiency virus; Nucleosidic analog; Protease inhibitor
• ISSN: 1058-4838; 1537-6591; 1537-6591
• DOI: 10.1086/338814

The relative potency and tolerability of multidrug regimens used to treat infants and children infected with human immunodeficiency virus type 1 (HIV-1) are largely unknown. In Pediatric AIDS Clinical Trials Group (PACTG) Protocol 377, 181 infants and children were assigned to receive stavudine (d4T) plus nevirapine (NVP) and ritonavir (RTV); d4T plus lamivudine (3TC) and nelfinavir (NFV); d4T plus NVP and NFV; or d4T plus 3TC, NVP, and NFV. Eleven additional children received d4T and NVP plus NFV given twice daily. All subjects had not previously received protease inhibitors or nonnucleoside reverse-transcriptase inhibitors and all had been immunologically stable while receiving reverse-transcriptase inhibitor therapy. After 48 weeks of therapy, 17 (41%) of 41 subjects receiving d4T-NVP-RTV, 13 (30%) of 44 receiving d4T-NVP-NFV, 21 (42%) of 50 receiving d4T-3TC and NFV (3 times daily), and 22 (52%) of 42 receiving d4T-3TC-NVP-NFV were still receiving their assigned therapy and had HIV-1 RNA suppression to ⩽400 copies/mL. These regimens were similar in their drug activity, but the 4-drug regimen offered slightly more durable suppression of viremia.